Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:
“AKT pathway inhibition in breast cancer may be broader than we think.
A new Foundation Medicine analysis of 51,767 breast cancer CGP samples shows:
- PIK3CA 37.4%
- PTEN 13.5%
- AKT1 5.4%
Capivasertib + fulvestrant real-world rwPFS:
- Standard qualifying variants: 170 days
- Rare/non-hotspot AKT pathway variants: 193 days
Key insights:
- Not all PTEN mutations are functionally equivalent
- Rare/non-hotspot AKT pathway variants may still benefit from capivasertib
- Biomarker selection may need to move beyond hotspot mutations alone
- PIK3CA / AKT1 / PTEN are largely mutually exclusive
- 16.2% of PIK3CA-mutant tumors harbor multiple PIK3CA mutations
- ~30% of AKT1 variants are non-E17K
Precision oncology is moving from mutation detection to functional pathway interpretation.”
Title: Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer
Authors: Jacqueline J. Tao, Saumya D. Sisoudiya, Hanna Tukachinsky, Alexa B. Schrock, Ericka M. Ebot, Smruthy Sivakumar, Ethan S. Sokol, Neil Vasan
Other Articles Featuring Ahmet Dirican On OncoDaily.